Tenderwize
Back to tender search

Open house discount agreements Infliximab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 20 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Infliximab, ATC L04AB02

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

No estimated value or framework maximum is provided. The actual revenue opportunity is unknown and depends on prescript...

If a nationwide or regional exclusive discount contract for Infliximab is concluded, open-house agreements terminate au...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Supply of Infliximab (ATC L04AB02) pharmaceutical products to AOK Bayern under discount agreements.
  • Non-exclusive framework agreements; all eligible pharmaceutical companies can participate.
Show full summary

This is an open-house model for non-exclusive discount agreements on the active substance Infliximab (ATC L04AB02) with AOK Bayern. It is not a formal procurement procedure but a voluntary admission system under § 130a Abs. 8 SGB V. All interested pharmaceutical companies that meet the eligibility criteria can conclude identical, non-negotiable discount agreements. The earliest contract start is 01.11.2024, and all contracts end on 31.10.2026. No estimated value is provided. The procedure is classified as an open procedure in the notice but explicitly stated to be outside procurement law.

Risks

No estimated value or framework maximum is provided. The actual revenue opportunity is unknown and depends on prescript...

If a nationwide or regional exclusive discount contract for Infliximab is concluded, open-house agreements terminate au...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Eligibility

  • Only pharmaceutical companies are eligible as potential contracting partners.

Administrative

  • Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submission of the signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Requirements may be incomplete.

Buyer

Location

München, DEU

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house discount agreements Infliximab

Non-exclusive discount agreements for Infliximab (ATC L04AB02) with AOK Bayern. All eligible pharmaceutical companies can join under identical terms. No selection or competition.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Oct 2024 - Oct 2026

Category

Pharmaceutical products

Deadline

Deadline Sep 05, 2026

Procurement Details

Publication date
16 Sep 2024
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
558403-2024

Documents (2)

Similar tenders